

Videnskabelige og faglige artikler

Fra Steno Diabetes Center 2006



Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional survey. *Diabet Med.* 2006 (Jul); 23(7): 750-756.

Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycemia in insulin-treated type 2 diabetes: a literature survey. *J Diabetes Complications* 2006 (Nov-Dec); 20 (6): 402-408.

Alizadeh BZ, Hanifi-Moghaddam P, Eerligh P, van der Slik AR, Kolb H, Kharagjitsingh AV, Pereira Arias AM, Ronkainen M, Knip M, Bonfanti R, Bonifacio E, Devendra D, Wilkin T, Giphart MJ, Koeleman BP, Nolsoe R, Mandrup-Poulsen T, Schloot NC, Roep BO; DIABMARKER Study Group. (2006) Association of interferon-gamma and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes. *Clin Exp Immunol* 145: 480-4.

Andersen G, Overgaard J, Albrechtsen A, Glümer C, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Studies of the association of the GNB3 825C>T polymorphism with components of the metabolic syndrome in white Danes. *Diabetologia* 2006 (Jan); 49 (1): 75-82.

Astrup AS, Tarnow L, Rossing P, Hansen BV, Hilsted J, Parving H-H. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. *Diabetes Care* 2006;29:334-339

Benitez S, Perez A, Sanchez-Quesada JL, Wägner AM, Rigla M, Arcelus R, Jorba O, Ordonez-Llanos J. Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control. *Diabetes Metab Res Rev.* 2006 Apr 24; [Epub ahead of print]

Bergholdt R, Eising S, Nerup J, Pociot F. Increased prevalence of Down syndrome in individuals with Type 1 diabetes mellitus in Denmark – a nation-wide population based study. *Diabetologia*, Published online 31.marts 2006. DOI: 10.1007/s00125-006-0231-6.

Bingley PJ, Gale EAM, The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (Mandrup-Poulsen T National coordinator). Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. *Diabetologia* (2006); 49: 881-890.

Blomhoff A, Olsson M, Johansson S, Akselsen HE, Pociot F, Nerup J, Kockum I, Cambon-Thomsen A, Thorsby E, Undlien DE, Lie BA. Linkage disequilibrium and haplotype blocks in the MHC vary in an HLA haplotype specific manner assessed mainly by DRB1*03 and DRB1*04 haplotypes. *Gene Immun*, doi:10.1038/sj.gene.6364272

Buermann B, Astrup A, Pedersen O, Black E, Holst C, Toubro S, Echwald S, Holst JJ, Rasmussen C, Sorensen TIA: Possible role of adiponectin and insulin sensitivity in mediating the favourable effects of lower body fat mass on blood lipids. *JCEM* 91: 1698-1704, 2006.

Cheyssac C, Dina C, Lepretre F, Vasseur-Delannoy V, Dechaume A, Lobbens S, Balkau B, Ruiz J, Charpentier G, Pattou F, Joly E, Prentki M, Hansen T, Pedersen O, Vaxillaire M, Froguel P: EIF4A2 is a positional candidate gene at the 3q27 locus linked to type 2 diabetes in French families. *Diabetes* 55: 1171-1176, 2006.

Christensen UB, Larsen PM, Fey S, Karlens AE, Pociot F, Nerup J, Sparre T. Different intracellular protein expression profiles are produced in islet destruction during spontaneous diabetes development in the BB-DP rat and in allograft rejection of BB-DP rat islets. *Autoimmunity* 39: 315-321.

DECODE Study Group – Qiao Q, Borch-Johnsen K et al. Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. *Diabetologia* 2006 (Dec); 49 (12): 2837-2846.

- Drivsholm T, Epløv LF, Davidsen M, Jørgensen T, Ibsen H, Hollnagel H, Borch-Johnsen K. Representativeness in population-based studies: a detailed description of non-response in a Danish cohort study. *Scand J Public Health*. 2006; 34 (6): 623-31.
- Eiberg H, Hansen L, Kjer B, Hansen T, Pedersen O, Bille M, Rosenberg T, Tranebjærg L: Autosomal dominant optic atrophy associated with hearing impairment and benign diabetes caused by a missense mutation in the WFS1 gene. *J Med Genet* 43: 435-440, 2006.
- Ek J, Hansen SP, Lajer M, Nicot C, Boesgaard TW, Pruhova S, Johansen A, Albrechtsen A, Yderstraede K, Lauenborg J, Parrizas M, Boj SF, Jørgensen T, Borch-Johnsen K, Damm P, Ferrer J, Lebl J, Pedersen O, Hansen T. A Novel -192c/g Mutation in the Proximal P2 Promoter of the Hepatocyte Nuclear Factor-4- $\{\alpha\}$ Gene (HNF4A) Associates With Late-Onset Diabetes. *Diabetes* 2006 (Jun); 55 (6):1869-1873.
- Fiegerlova E, Pruhova E, Dittertova L, Lebl J, Pinterova D, Kolostova K, Cerna M, Pedersen O, Hansen T: Aetiological heterogeneity of a symptomatic hyperglycaemia in children and adolescents. *Eur J Pediatr* 165: 446-452, 2006.
- Forouhi NG, Balkau B, Borch-Johnsen K, Dekker J, Glümer C, Qiao Q, Spijkerman A, Stolk R, Tabac A, Wareham NJ, On behalf of EDEG. The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. *Diabetologia* 2006 (May); 49 (5): 822-827.
- Frobose H, Ronn SG, Heding PE, Mendoza H, Cohen P, Mandrup-Poulsen T, Billestrup N. Suppressor of cytokine signalling (SOCS)-3 inhibits IL-1 signaling by targeting the TRAF-6/TAK1 complex. *Mol Endocrinol* (2006) Epub. ahead of print.
- Glümer C, Vistisen D, Borch-Johnsen K, Colagiuri S; DETECT-2 Collaboration. Risk scores for type 2 diabetes can be applied in some populations but not all. *Diabetes Care* 2006 (Feb); 29 (2): 410-414.
- Grarup N, Urhammer SA, Ek J, Albrechtsen A, Glümer C, Borch-Johnsen K, Jørgensen T, Hansen T, Pedersen O. Studies of the relationship between the ENPP1 K121Q polymorphism and type 2 diabetes, insulin resistance and obesity in 7,333 Danish white subjects. *Diabetologia* 2006 (Sep); 49(9): 2097-2104.
- Grunnet L, Poulsen P, Klarlund Pedersen B, Mandrup-Poulsen T, Vaag A. Plasma cytokine levels in young and elderly twins: genes versus environment and relation to in vivo insulin action. *Diabetologia*. Feb;49(2):343-50. 2006.
- Hainerova I, Toreskov SS, Ek J, Finkova M, Borch-Johnsen K, Jørgensen T, Madsen OD, Lebl J, Hansen T, Pedersen O. Association between Neuromedin U gene variants and overweight and obesity. *J Clin Endocrinol Metab*. 2006 (Dec); 91 (12): 5057-5063.
- Harries LW, Ellard S, Stride A, Vaxillaire M, Tuomi T, Barbetti E, Njolstad PR, Hansen T, Costa A, Congret I, Pedersen O, Sovik O, Lorini R, Froguel P, Morgan NG, Hattersley AT (2006) Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. *Hum Mol Genet* 15: 2216-2224.
- Haugaard SB, Madsbad S, Hoeyt CE, Vaag A. Dietary intervention increases n-3 long-chain polyunsaturated fatty acids in skeletal muscle membrane phospholipids of obese subjects. Implications for insulin sensitivity. *Clinical Endocrinology (Oxf)*. Feb;64(2):169-78. 2006.
- Hillestroem RP, Weimann A, Jensen BC, Vaag A, Poulsen EH. Consequences of low birth weight on urinary excretion of DNA markers of oxidative stress in young men. *Scand J Clin Lab Invest* 66(5):363-70.
- Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK, Langer B, Thorand B, Klopp N, Hamid YH, Pedersen O, Hansen T, Lyssenko V, Groop L, Meisinger C, Döring A, Löwel H, Lieb W, Hengstenberg C, Rathmann W, Martin S, Stephens JW, Ireland H, Mather H, Miller GJ, Stringham HM, Boehnke M, Tuomilehto J, Boeing H, Möhlig M, Spranger J, Pfeiffer A, Wernstedt I, Niklason A, López-Bermejo A, Fernández-Real JM, Hanson RL, Gallart L, Vendrell J, Tsiavou A, Hatzigeorgaki E, Humphries SE, Wichmann HE, Herder C, Illig T. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. *Diabetes*. 2006 Oct;55(10):2915-21.
- Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Snapinn SM, Wan Y, Lyle PA. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus

atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. *Diabetes Care* 2006 (Mar); 29 (3): 595-600.

Jensen DP, Urhammer SA, Eiberg H, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Variation in CAPN10 in relation to type 2 diabetes, obesity and quantitative metabolic traits: Studies in 6018 whites. *Mol Genet Metab.* 2006 (Dec); 89 (4): 360-367.

Johansen A, Jensen DP, Bergholdt R, Mortensen HB, Pociot F, Nerup J, Hansen T, Pedersen O, The Danish Society of Childhood Diabetes: IRS1, KCNJ11, PPAR γ 2 and HNF1- α : do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1, and type 2 diabetes? *Diabetes, Obesity and Metabolism* 1: 75-82, 2006.

Jorgensen JO, Jessen N, Pedersen SB, Vestergaard E, Gormsen L, Lund SA, Billestrup N. GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. *Am J Physiol Endocrinol Metab.* 2006 Nov;291(5):E899-905.

Jorgensen ME, Borch-Johnsen K, Bjerregaard P. Lifestyle modifies obesity-associated risk of cardiovascular disease in a genetically homogeneous population. *Am J Clin Nutr.* 2006 (Jul); 84(1): 29-36.

Jorgensen ME, Moustgaard H, Bjerregaard P, Borch-Johnsen K. Gender differences in the association between westernization and metabolic risk among Greenland Inuit. *Eur J Epidemiol.* 2006; 21 (10): 741-748.

Karlsen AE, Stoerling ZM, Sparre T, Larsen MR, Mahmood A, Stoerling J, Roepstorff P, Wrzesinski K, Larsen PM, Fey S, Nielsen K, Heding P, Ricordi C, Johannesen J, Kristiansen OP, Christensen UB, Kochum I, Luthman H, Nerup J, Pociot F. Immune-mediated β -cell destruction in vitro and in vivo – A pivotal role for galectin-3. *Biochem Bioph Res Co* 344: 406-415.

Kessel L, Jorgensen T, Glümer C, Larsen M. Early lens aging is accelerated in subjects with a high risk of ischemic heart disease: an epidemiologic study. *BMC Ophthalmol* 2006 (Apr); 18;6:16.

Lajer M, Schjoedt KJ, Jacobsen P, Tarnow L, Parving H-H. Aldosterone synthase (CYP11B2)-344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients. *Diabetic Medicine* 2006;23:675-680.

Larsen CM, Doessing MG, Papa S, Franzoso G, Billestrup N, Mandrup-Poulsen T. Growth arrest- and DNA-damage-inducible 45 β gene inhibits c-Jun N-terminal kinase and extracellular signal-regulated kinase and decreases IL-1 β -induced apoptosis in insulin-producing INS-1E cells. *Diabetologia* (2006) Epub ahead of print.

Lau C, Toft U, Tetens I, Richelsen B, Jorgensen T, Borch-Johnsen K, Glümer C. Association between dietary glycemic index, glycemic load, and body mass index in the Inter99 study: is underreporting a problem? *Am J Clin Nutr.* 2006 (Sep); 84 (3): 641-645.

Martinsen N, Jorgensen ME, Bjerregaard P, Krasnik A, Carstensen B, Borch-Johnsen K. Predictions of type 2 diabetes and complications in Greenland in 2014. *Int J Circumpolar Health.* 2006 (Jun); 65(3): 243-252.

Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Tajima N, Hu G, Borch-Johnsen K. Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study. *Eur J Cardiovasc Prev Rehabil.* 2006 (Aug); 13(4): 555-561.

Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving H-H, Goldschmeding R, van Nieuwenhoven FA. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. *Diabetes Care* 2006;29:83-88

Nielsen LB, Mortensen HB, Chiarelli F, Holl R, Swift P, de Beaufort C, Pociot F, Hougaard P, Gammeltoft S, Knip M, Hansen L, on behalf of the Hvidoere study group. Impact of IDDM2 on disease pathogenesis and progression in children with newly diagnosed type 1 diabetes: reduced insulin antibody titres and preserved beta-cell function. *Diabetologia* 49:71-74, 2006.

Nolsoe RL, Hamid YH, Pociot F, Paulsen S, Andersen KM, Borch-Johnsen K, Drivsholm T, Hansen T, Pedersen O, Mandrup-Poulsen T. Association of a microsatellite in FASL to type II diabetes and of the FAS-670G>A genotype to insulin resistance. *Genes Immun.* 2006 (Jun); 7 (4): 316-321.

Olsen MH, Christensen MK, Hansen TW, Gustafsson F, Rasmussen S, Wachtell K, Borch-Johnsen K, Ibsen H, Jorgensen T, Hildebrandt P. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. *J Hypertens* 2006 (Apr); 24 (4): 655-661.

Ortis F, Cardozo AK, Crispim D, Stoerling J, Mandrup-Poulsen T, Eizirik DL. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained and non-oscillatory NFkB activation. *Mol Endocrinol* (2006) Epub. ahead of print.

Ozanne SE, Jensen CB, Tingey KJ, Martin-Gronert MS, Grunnet L, Brons C, Storgaard H, Vaag A. Decreased protein levels of key insulin signalling molecules in adipose tissue from young men with a low birthweight – potential link to increased risk of diabetes? *Diabetologia* 49(12):2993-2999.

Parving H-H, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. *Kidney International* 2006;69:2057-2063.

Petersen LG, Stoerling J, Heding P, Lis S, Berezin V, Saldeen J, Billestrup N, Bock E, Mandrup-Poulsen T. IL-1 β -induced pro-apoptotic signalling is facilitated by NCAM/FGF receptor signalling and inhibited by the C3d ligand in the INS-1E rat beta cell line. *Diabetologia* (2006); Epub ahead of print.

Petersen M, Taylor MA, Saris WH, Verdich C, Toubro S, Macdonald I, Rossner S, Stich V, Guy-Grand B, Langin D, Martinez JA, Pedersen O, Holst C, Soerensen TI, Astrup A: Randomized, multi-center trial of two hypo-energetic diets in obese subjects: high-versus low-fat content. *Int J Obes* 30: 5525-5560, 2006.

Poulsen P, Vaag A. The intrauterine environment as reflected by birth size and twin and zygosity status influences insulin action intracellular glucose metabolism in an age- or time-dependent manner. *Diabetes*. Jun;55(6):1819-25. 2006. 3

Rasmussen LM, Tarnow L, Hansen TK, Parving H-H, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. *European Journal of Endocrinology* 2006;154:75-81.

Rossing P, Rossing K, Gaede P, Pedersen O, Parving H-H. Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. *Diabetes Care* 2006;29:1024-1030.

Rubak S, Sandbaek A, Lauritzen T, Borch-Johnsen K, Christensen B. An education and training course in motivational interviewing influence: GPs' professional behaviour--ADDITION Denmark. *Br J Gen Pract*. 2006 (Jun); 56(527): 429-436.

Sanchez-Quesada JL, Benitez S, Perez A, Wägner AM, Rigla M, Carreras G, Vila L, Camacho M, Arcelus R, Ordonez-Llanos J. The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity. *Diabetologia*. 2005;48:2162-9. Epub 2005 Aug 18.

Santos JL, Boutin P, Verdich C, Holst C, Larsen LH, Toubro S, Dina C, Saris WH, Blaak EE, Hoffstedt J, Taylor MA, Polak J, Clement K, Langin D, Astrup A, Froguel P, Pedersen O, Sorensen TI, Martinez JA, the Nugenob Consortium (2006) Genotype-by-nutrient interactions assessed in European obese women: a case-only study. *Eur J Nutr* 45: 454-462.

Schjoedt KJ, Lajer M, Andersen S, Tarnow L, Rossing P, Parving H-H. Aldosterone synthase (CYP11B2)-344-T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. *Scand J Clin Lab Invest* 2006;66:173-180.

Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving H-H. Beneficial impact of spironolactone in diabetic nephropathy. *Kidney International* 2005;68:2829-2836

Skovhus KV, Bergholdt R, Erichsen C, Sparre T, Nerup J, Karlsen AE, Pociot F. Identification and characterization of secretagogen promoter activity. *Scand J Immunol* 64: 639-645.

Storgaard H, Poulsen P, Ling C, Groop L, Vaag A. Genetic and non-genetic determinants of skeletal muscle GLUT4 mRNA levels and insulin action in twins. *J Clinical Endocrinology Metab*. 2006 Feb;91(2):702-8.

Sorensen TI, Boutin P, Taylor MA, Larsen LH, Verdich C, Petersen L, Holst C, Echwald SM, Dina C, Toubro S, Petersen M, Polak J, Clement K, Martinez JA, Langin D, Oppert JM, Stich V, Macdonald I, Arner P, Saris WH,

Pedersen O, Astrup A, Froguel P (2006) Genetic polymorphisms and weight loss in obesity: a randomised trial of hypo-energetic high- versus low-fat diets. *PLoS Clin Trials*. 2006 Jun;1(2):e12.

Theil PK, Kessel L, Hansen T, Lund-Andersen H, Pedersen O, Larsen M (2006) Lens fluorescence in relation to glucose tolerance and genetic predisposition to type 2 diabetes mellitus in a population-based study. *Curr Eye Res* 31: 733-738.

Toreskov SS, Larsen LH, Andersen G, Albrechtsen A, Glümer C, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Variants in the 5' region of the neuropeptide Y receptor Y2 gene (NPY2R) are associated with obesity in 5,971 white subjects. *Diabetologia*. 2006 (Nov); 49 (11): 2653-2658.

Tsuchiya T, Schwarz PEH, del Bosque-Plata L, Hayes MG, Dina C, Froguel P, Towers GW, Fischer S, Temelkova-Kurktschiev T, Rietzsch H, Graessler J, Vcelak J, Palyzova D, Selisko T, Bendlova B, Schulze J, Julius U, Hanefeld M, Weedon MN, Evans JC, Frayling TM, Hattersley AT, Orho-Melander M, Groop L, Malecki MT, Hansen T, Pedersen O, Fingerlin TE, Boehnke M, Hanis CL, Cox NJ, Bell GI (2006) Association of the calpain 10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. *Mol Genet Metab* 89: 174-184.

van Hove EC, Hansen T, Dekker JM, Reiling E, Nijpels G, Jorgensen T, Borch-Johnsen K, Hamid YH, Heine RJ, Pedersen O, Maassen JA, 't Hart LM. The HADHSC gene encoding short-chain L-3-hydroxyacyl-CoA dehydrogenase (SCHAD) and type 2 diabetes susceptibility: the DAMAGE study. *Diabetes* 2006 (Nov); 55 (11): 3193-3196.

Walsh MG, Zgibor J, Borch-Johnsen K, Orchard TJ; DiaComp Investigators. A multinational assessment of complications in type 1 diabetes: the DiaMond substudy of complications (DiaComp) level 1. *Diab Vasc Dis Res*. 2006 (Sep); 3 (2): 84-92.

Wegner L, Andersen G, Albrechtsen A, Sparso T, Glümer C, Borch-Johnsen C, Jorgensen T, Hansen T, Pedersen O. Large-scale study of the -232C > G polymorphism of PCK1 in Type 2 diabetes. *Diabet Med*. 2006 (Oct); 23 (10): 1140-1144.

Zaitseva, Sharoyko V, Stoerling J, Efendic S, Guerin C, Mandrup-Poulsen T, Nicotera P, Berggren P-O, Zaitsev SV (2006) RX871024 reduces nitric oxide production but does not protect against pancreatic β -cell death induced by proinflammatory cytokines. *Biochem Biophys Res Commun*; 347: 1121-8.

Oversigtsartikler, lærebøger m.m.

Bergholdt R, McDermott MF, Pociot F. Endocrine diseases: Type 1 diabetes. In *Immunogenetics of autoimmune diseases*, Ed Oksenberg J. Landes Bioscience, Georgetown, TX, ISBN: 1-58706-173-2, 2006, pp 28-40.

Bergholdt R, Heding P, Ronn SG, Størling J, Tonnesen J, Pociot F, Mandrup-Poulsen T. Type I Diabetes, Molecular, Cellular and Clinical Immunology. Online Edition. Second edition. (2006) Editor George S. Eisenbarth. Chapter 5. Type 1 Diabetes Mellitus: an Inflammatory Disease of the Islet. http://www.uchsc.edu/misc/diabetes/books/type1/type1_ch5.html

Bergholdt R, Pociot F: Type 1 and 2 Diabetes. In *Cytokine gene polymorphisms in multifactorial conditions*, 1.ed. Vandenbroeck K, Ed. Boca Raton, Florida, USA, CRC Press, Taylor and Francis Group LLC, p. 305-319.

Borch-Johnsen K. The Metabolic syndrome in a global perspective. Significance for public health. *Ugeskrift for læger* 2006 (Sep) 4; 168 (36): 3032-3034.

Carstensen B. Demography and epidemiology: Age-Period-Cohort models in the computer age. Technical Report 06.1, Department of Biostatistics, University of Copenhagen, <http://www.pubhealth.ku.dk/bs/publikationer/rr-06-1.pdf>, 2006.

Carstensen B. Demography and epidemiology: Practical use of the Lexis diagram in the computer age, or: Who needs the Cox-model anyway? Technical Report 06.2, Department of Biostatistics, University of Copenhagen, <http://www.pubhealth.ku.dk/bs/publikationer/rr-06-2.pdf>, 2006.

Echwald SM, Larsen PJ, Pedersen OB, Sørensen TIA (2006) The genetics of obesity. *Ugeskrift for læger* 168: 150-152.

Gaede P, Parving H-H, Pedersen O (2006) PROactive study. *Lancet* 367: 23-24.

Jacobsen PK, Tarnow L, Parving H-H. Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy? *Kidney International* 2006;69:1293-1295.

Jorgensen ME, Borch-Johnsen K, Bjerregaard P. Type 2 Diabetes og Hjertekarsygdom – det 21. Århundredes store Folkesundhedsproblem i Grønland? *Månedsskrift for Praktiserende Lægegerning* 2006; 3: 311-318.

Larsen PJ, Echwald SM, Sørensen TIA, Pedersen OB (2006) Molecular pathogenesis in monogenic and polygenic obesity. *Ugeskrift for læger* 168: 152-155.

Parving H-H, Rossing P. Renoprotective effects of renin-angiotensin-system inhibitors. *The Lancet* 2006;367:898-899 (Letter).

Pociot F. Genetics of type 1 diabetes. *Int Diabetes Monitor* 18: 10-16, 2006.

Pociot F. The relevance of international consortia in studies on the pathogenesis of type 1 diabetes. The role of ET1DGN. *DMRR*, (DOI 10.1002/dmrr.610).

Rich SS, Concannon P, Erlich H, Julier C, Morahan G, Nerup J, Pociot F, Todd JA. The type 1 diabetes genetics consortium. *Ann NY Acad Sci* 1079: 1-8.

Rossing P, Cooper ME, Parving H-H. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. *Diabetes Care* 2006;29:747-48 (Letter).

Thomas MC, Cooper ME, Rossing K, Parving H-H. Anaemia in diabetes: is there a rationale to TREAT? *Diabetologia* 2006; 49(6):1151-57.

Vaag A. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. *Endocr Pract.* Jan-Feb;12 suppl 1:8992. 2006.

Vaag A, Brons C, Appel JS, Toubro S. Metabolic consequences of overeating. *Ugeskrift for læger* Jan 9;168(2):183-7. 2006. Review. Danish.

Vaag A, Jensen CB, Poulsen P, Brøns C, Pilgaard K, Grønnet L, Vielwerth S, Alibegovic A. Metabolic aspects of insulin resistance in individuals born small for gestational age. *Horm Res.*; 65 Suppl 3:137-43. 2006.

WHO/IDF Consultation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. Borch-Johnsen K member of committee and reviewing board, WHO, Geneva, 2006.

Ph.d.- afhandlinger

Akram K. Hypoglycaemia in patients with type 2 diabetes treated with insulin. Københavns Universitet.

Gylvin T. A systems biology approach to understand T1D pathogenesis. Københavns Universitet.

Hoei-Hansen T. Hypoglykæmi ved type 1 diabetes vurderet ved kontinuerlig glukosemonitorering. Københavns Universitet.

Johansen A. Genetic aspects of pancreatic β -cell dysfunction in type 1 diabetes, type 2 diabetes and maturity onset diabetes of the young. Københavns Universitet.

Larsen LH. Genetic aspects of human obesity. Studies of the candidate genes: MC4R, GHSR, ghrelin, PPAR γ 2P and ESRRA. Københavns Universitet.

Larsen TM. Aspects of the molecular aetiology of obesity and co-morbidities with a focus on impact of PPAR γ gene variants and responses to dietary supplementation with conjugated fatty acids. Københavns Universitet.

Disputatser

Gaede PH. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: Rationale and effect on late-diabetic complications". Københavns Universitet.

Johannesen J. Den genetiske baggrund for og immunologiske betydning af den IL-1 inducerede ændrede proteinekspression i betaceller. Københavns Universitet.

Specialeafhandlinger

Albrechtsen A. Modelling higher-order gene-gene-environment interactions in population-based association studies using Markov chain Monte Carlo.

Andersen MK. Genetic and epidemiological studies of variation in PTF1A, FAAH, DIO2, and LIPC: candidate genes in the pathogenesis of maturity-onset diabetes of the young, type 2 diabetes, obesity, and dyslipidemia.

Andreasen CH. Genetic and epidemiological studies of variation in PTF1A, FAAH, DIO2, and LIPC: candidate genes in the pathogenesis of maturity-onset diabetes of the young, type 2 diabetes, obesity, and dyslipidemia.

Castella SI. The MAMSE method: a mixture model for association studies of multiple SNP effects of a given trait.

Laigaard KK. Impact of abdominal fat distribution and VO2max on insulin resistance in low birth weight subjects and matched controls.

Lund ASQ. Impact of abdominal fat distribution and VO2max on insulin resistance in low birth weight subjects and matched controls.

Sparsoe T. Studies of genetic and functional variation in ESRRB, APOA5, and NEUROD1 in relation to discrete and quantitative metabolic traits in humans.